Double hit and double expressors in lymphoma: Definition and treatment
暂无分享,去创建一个
[1] D. Housman,et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.
[2] A. Zetterberg,et al. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[3] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[4] S. Lowe,et al. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. , 2001, Blood cells, molecules & diseases.
[5] R. Fisher,et al. The epidemiology of non-Hodgkin's lymphoma , 2004, Oncogene.
[6] Ryan T. Phan,et al. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells , 2004, Nature.
[7] Richard Simon,et al. Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.
[8] F. Jardin,et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.
[9] M. Dimopoulos,et al. CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group , 2007, Cancer journal.
[10] L. Staudt,et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.
[11] L. Penn,et al. Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.
[12] A. Letai,et al. Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.
[13] B. Hoffman,et al. Apoptotic signaling by c-MYC , 2008, Oncogene.
[14] A. Rosenwald,et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.
[15] S. Yoon,et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type , 2008, Histopathology.
[16] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[17] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[18] N. Nakamura,et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations , 2009, Haematologica.
[19] Aggressive lymphomas. , 2010, The New England journal of medicine.
[20] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Basso,et al. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. , 2010, Advances in immunology.
[22] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] P. Hammerman,et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high‐risk patients with diffuse large B‐cell lymphoma , 2010, Cancer.
[24] L. Rimsza,et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma , 2010, Haematologica.
[25] F. Jardin,et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. , 2011, The Lancet. Oncology.
[26] W. Chan,et al. Gains of MYC locus and outcome in patients with diffuse large B‐cell lymphoma treated with R‐CHOP , 2011, British journal of haematology.
[27] A. Rosenwald,et al. MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .
[28] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Lauritzen,et al. Double‐hit BCL2/MYC translocations in a consecutive cohort of patients with large B‐cell lymphoma – a single centre's experience , 2012, European journal of haematology.
[30] K. Basso,et al. Roles of BCL6 in normal and transformed germinal center B cells , 2012, Immunological reviews.
[31] Ryan D. Morin,et al. BCL2 mutations in diffuse large B-cell lymphoma , 2012, Leukemia.
[32] K. Young,et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Rosenwald,et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.
[34] J. Briones,et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.
[35] W. Choi,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[36] R. Spang,et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma , 2014, Haematologica.
[37] Michael L. Wang,et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience , 2014, British journal of haematology.
[38] D. Huang,et al. Targeting BCL2 for the treatment of lymphoid malignancies. , 2014, Seminars in hematology.
[39] P. Juszczyński,et al. MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. , 2014, Biochimica et biophysica acta.
[40] Scott E. Smith,et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. , 2014, Blood.
[41] S. Swerdlow. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. , 2014, Hematology. American Society of Hematology. Education Program.
[42] S. Schuster,et al. ‘Double‐Hit’ cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients , 2014, British journal of haematology.
[43] E. Campo,et al. MYC alterations in diffuse large B-cell lymphomas. , 2015, Seminars in hematology.
[44] D. Scott. Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic? , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[45] A. Rosenwald,et al. Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations , 2015, The American journal of surgical pathology.
[46] K. Young,et al. MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma , 2015, Oncotarget.
[47] S. Barrans,et al. The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit , 2015, The journal of pathology. Clinical research.
[48] C. Copie-Bergman,et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. , 2015, Blood.
[49] N. Gebauer,et al. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations , 2015, Leukemia & lymphoma.
[50] K. Basso,et al. Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.
[51] S. Schuster,et al. Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis , 2015, British journal of haematology.
[53] Outcome of Patients with Double-Expressor Lymphomas (DELs) Treated with R-CHOP or R-EPOCH , 2016 .
[54] Sonali M. Smith,et al. Outcomes of MYC‐associated lymphomas after R‐CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704 , 2016, British journal of haematology.
[55] A. Zelenetz,et al. Impact of oncogene rearrangement patterns on outcomes in patients with double‐hit non‐Hodgkin lymphoma , 2016, Cancer.
[56] R. Advani,et al. The World Health Organization Classification of Lymphoid Neoplasms , 2013 .
[57] Ken H. Young,et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma , 2015, Oncotarget.
[58] Scott E. Smith,et al. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable , 2016, British journal of haematology.
[59] R. Gascoyne,et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. , 2016, Blood.
[60] Scott E. Smith,et al. Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303 , 2016 .
[61] J. Vose,et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] P. Papenhausen,et al. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects , 2017, Genes.
[63] Y. Oki,et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma , 2017, Modern Pathology.
[64] Stephen J. Schuster,et al. Chimeric Antigen Receptor T Cells in Refractory B‐Cell Lymphomas , 2017, The New England journal of medicine.
[65] L. Medeiros,et al. Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma , 2017, Modern Pathology.
[66] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[67] R. Levy,et al. Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.
[68] W. Chan,et al. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Leonard,et al. Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] Philipp W. Raess,et al. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma , 2018, Leukemia & lymphoma.
[71] W. Chan,et al. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.